Cambridge Healthtech Institute’s Inaugural
Analytical Intelligence
Modernizing Analytical Development via Expanded Data Access, AI, and Predictive Modeling
January 19-20, 2027
The biopharmaceutical industry is generating analytical data at a scale and complexity that traditional tools and workflows were not designed to handle. Cambridge Healthtech Institute's Inaugural Analytical Intelligence Conference addresses the organizational, computational, and regulatory dimensions of this shift—from the foundational work of making historical data usable, to the deployment of adaptive automated systems, to the challenge of building predictive tools for an increasingly diverse therapeutic landscape, to the emerging question of how AI-generated evidence will be received by global regulators.
Coverage will include, but is not limited to:
OVERCOMING LIMITATIONS IN DATA INFRASTRUCTURE
- Building machine learning-ready datasets from legacy lab systems, instrument records, and PDF-bound data
- Ensuring data traceability and quality through open data standards in regulated environments
- Pre-competitive frameworks for machine learning model documentation and reuse
- Timelines and investment required to convert historical analytical data into usable training sets
AUTOMATION AND AI IN ANALYTICAL WORKFLOWS
- Transitioning from scripted automation to intelligent, adaptive systems
- Do third-party or in-house machine learning tools outperform vendor-packaged algorithms?
- Human-in-the-loop design for AI-assisted data review in regulated environments
- How close is the industry to fully autonomous quality testing?
PREDICTIVE MODELING FOR COMPLEX AND EMERGING MODALITIES
- Analytical characterization challenges for ADCs, AAVs, LNPs, and cell and gene therapy products
- Building predictive models when training data is scarce
- Immunogenicity and anti-drug antibody prediction as an analytical and CMC responsibility
- Computational predictions in regulatory submissions: current practice and future expectations
REGULATORY PATHWAY FOR AI-GENERATED ANALYTICAL EVIDENCE
- FDA and EMA guidance and requirements for AI-assisted analytical submissions
- Documentation expectations for training data, model validation, and uncertainty
- What public submission records reveal about current practice and transparency gaps
- Applying existing analytical standards to AI-assisted tools
- Regional divergence: FDA, EMA, and APAC approaches compared
The deadline for priority consideration is June 26, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: